MARIA KRISTINEGULE-MONROEMARIA KRISTINE GULE-MONROE11754GULE-MONROE, MARIA KRISTINEAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonDiagnostic RadiologyEndocrine Neoplasia & HDHead & Neck SurgeryInvestigational Cancer TherapeuticsLeukemiaPalliative Care & Rehabilitation MedicineSurgical OncologyMD AndersonSTEVEN ISHERMANSTEVEN I SHERMAN8436SHERMAN, STEVEN IProfessorRAYMOND ESAWAYARAYMOND E SAWAYA8456SAWAYA, RAYMOND EProfessorVIVEKSUBBIAHVIVEK SUBBIAH9518SUBBIAH, VIVEKAssistant ProfessorSTEPHEN YENZENLAISTEPHEN YENZEN LAI9565LAI, STEPHEN YENZENAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorMARIA ECABANILLASMARIA E CABANILLAS8975CABANILLAS, MARIA EAssociate ProfessorELIZABETH GARDNERGRUBBSELIZABETH GARDNER GRUBBS9340GRUBBS, ELIZABETH GARDNERAssociate Professor74Professor10Assistant Professor14Associate Professor1515 Holcombe Blvd.Houston77030TX1.073290.0070569121research areas1.422990.027034990coauthor of23.0383.4519260similar to1127selected publicationsALIHAIDERALI HAIDER11891HAIDER, ALIAssistant ProfessorJASON MICHAELJOHNSONJASON MICHAEL JOHNSON11908JOHNSON, JASON MICHAELAssistant Professor21220477Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SYClinical cancer research : an official journal of the American Association for Cancer ResearchTargeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011 Apr 15; 17(8):2281-91.Clin Cancer Res2011-01-10T00:00:002011Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Authorship 3726212Authorship 3726225Authorship 372623122367702Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, El-Naggar AK, Myers JNHead & neckEarly postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck. 2013 Mar; 35(3):321-8.Head Neck2012-02-24T00:00:002012Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.19380367Sano D, Choi S, Milas ZL, Zhou G, Galer CE, Su YW, Gule M, Zhao M, Zhu Z, Myers JNArchives of otolaryngology--head & neck surgeryThe effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg. 2009 Apr; 135(4):411-20.Arch Otolaryngol Head Neck Surg2009-04-01T00:00:002009The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue.29161986Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas METhyroid : official journal of the American Thyroid AssociationReal-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.Thyroid2017-12-21T00:00:002017Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.Authorship 8887699D013964Disorders36218630.446935Thyroid NeoplasmsD018278Disorders2517140.620327Carcinoma, NeuroendocrineD011744Chemicals & Drugs1643140.835147PyrimidinonesAuthorship 9350753Authorship 9393661029996921Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas MEJournal for immunotherapy of cancerSalvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68.J Immunother Cancer2018-07-11T00:00:002018Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.30046660Machol K, Jankovic J, Vijayakumar D, Burrage LC, Jain M, Lewis RA, Fuller GN, Xu M, Penas-Prado M, Gule-Monroe MK, Rosenfeld JA, Chen R, Eng CM, Yang Y, Lee BH, Moretti PM, Undiagnosed Diseases Network, Dhar SUNeurology. GeneticsAtypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma. Neurol Genet. 2018 Aug; 4(4):e248.Neurol Genet2018-07-20T00:00:002018Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma.D018315Disorders17250.96104Glioma, SubependymalNeurosurgeryAuthorship 946006331046173Jethanandani A, Chen MM, Gule-Monroe MK, Morrison WH, Lai SY, Johnson JMHead & neckIncidental detection of oropharyngeal cancer with fluciclovine PET. Head Neck. 2019 08; 41(8):E141-E145.Head Neck2019-05-02T00:00:002019Incidental detection of oropharyngeal cancer with fluciclovine PET.D065646Disorders742570.793756Thyroid Carcinoma, AnaplasticAuthorship 947840231139567Jethanandani A, Gule-Monroe MK, Chen M, Johnson JMFrontiers in oncologyExtraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation. Front Oncol. 2019; 9:373.Front Oncol2019-05-08T00:00:002019Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation.Authorship 952197831319771Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas METhyroid : official journal of the American Thyroid AssociationComplete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.Thyroid2019-08-01T00:00:002019Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Authorship 957825231648931Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EGSurgeryNovel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.Surgery2019-10-21T00:00:002019Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma.Authorship 979295432181729Zhou Z, Sanders JW, Johnson JM, Gule-Monroe MK, Chen MM, Briere TM, Wang Y, Son JB, Pagel MD, Li J, Ma JRadiologyComputer-aided Detection of Brain Metastases in T1-weighted MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors. Radiology. 2020 05; 295(2):407-415.Radiology2020-03-17T00:00:002020Computer-aided Detection of Brain Metastases in T1-weighted MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors.Authorship 980123732216548Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MCThyroid : official journal of the American Thyroid AssociationAcquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020 09; 30(9):1288-1296.Thyroid2020-05-07T00:00:002020Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.Authorship 9988234Authorship 999491432922843Learned KO, Vu TH, Choi JM, Gule-Monroe MK, Pytynia KB, Ginsberg LEBJR case reportsPurulent chondritis of thyroid cartilage. BJR Case Rep. 2020 Sep 01; 6(3):20200013.BJR Case Rep2020-06-02T00:00:002020Purulent chondritis of thyroid cartilage.32937104Zhou Z, Sanders JW, Johnson JM, Gule-Monroe M, Chen M, Briere TM, Wang Y, Son JB, Pagel MD, Ma J, Li JRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyMetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging. Radiother Oncol. 2020 12; 153:189-196.Radiother Oncol2020-09-13T00:00:002020MetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging.Authorship 1004774433169506Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas MHead & neckNeoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12.Head Neck2020-11-09T00:00:002020Neoadjuvant selpercatinib for advanced medullary thyroid cancer.Authorship 1017636333942701Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BSLeukemia & lymphomaPrognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.Leuk Lymphoma2021-05-04T00:00:002021Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.Authorship 1025886334293707Khalil M, Zafereo M, Gule-Monroe M, Sherman SI, Bell DAnnals of diagnostic pathologyNon-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma. Ann Diagn Pathol. 2021 Oct; 54:151791.Ann Diagn Pathol2021-07-15T00:00:002021Non-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma.Authorship 1027493934377987Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado MNeuro-oncology advancesClinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079.Neurooncol Adv2021-06-22T00:00:002021Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience.Authorship 1034981834867723Johnson JM, Chen MM, Rohren EM, Prabhu S, Chasen B, Mawlawi O, Liu HL, Gule-Monroe MKFrontiers in neurologyDelayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing. Front Neurol. 2021; 12:740280.Front Neurol2021-11-16T00:00:002021Delayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing.Authorship 1039622435135166Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas MEJCO precision oncologyCirculating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Nov; 2:1-11.JCO Precis Oncol2018-11-01T00:00:002018Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.Authorship 10439551035426054Haider AS, El Ahmadieh TY, Haider M, Hatanpaa KJ, Pinho MC, Mickey BE, Sawaya R, Fuller GN, Schomer DF, Gule-Monroe MNeuroradiologyImaging characteristics of 4th ventricle subependymoma. Neuroradiology. 2022 Sep; 64(9):1795-1800.Neuroradiology2022-04-15T00:00:002022Imaging characteristics of 4th ventricle subependymoma.Authorship 10607932Authorship 10606741436503246Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo METhyroid : official journal of the American Thyroid AssociationNeoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132.Thyroid2023-01-01T00:00:002023Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.36074155Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NUClinical cancer research : an official journal of the American Association for Cancer ResearchPreclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin Cancer Res. 2023 01 04; 29(1):174-182.Clin Cancer Res2023-01-04T00:00:002023Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.Authorship 1064741436856048Contrera KJ, Shakibai N, Su SY, Gule-Monroe MK, Roberts D, Brahimaj B, Williams MD, Ferrarotto R, Phan J, Gunn B, Raza S, DeMonte F, Hanna EYOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck SurgeryImpact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440.Otolaryngol Head Neck Surg2023-03-01T00:00:002023Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma.Authorship 1067994937114244Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NKNeuro-oncology advancesCharacterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.Neurooncol Adv2023-04-13T00:00:002023Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience.Authorship 1083137637944358Haider AS, McCutcheon IE, Ene CI, Fuller GN, Schomer DF, Gule-Monroe M, DeMonte F, Ferguson SD, Lang FF, Prabhu SS, Raza SM, Suki D, Weinberg JS, Sawaya RJournal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaSubependymomas of the fourth ventricle: To operate or not to operate? J Clin Neurosci. 2023 Dec; 118:147-152.J Clin Neurosci2023-11-07T00:00:002023Subependymomas of the fourth ventricle: To operate or not to operate?Authorship 1086994438226606Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas METhyroid : official journal of the American Thyroid AssociationCheckpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346.Thyroid2024-02-13T00:00:002024Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professor